ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 227 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $909,211 | +47.3% | 29,039 | -1.9% | 0.03% | +34.8% |
Q3 2023 | $617,072 | -5.2% | 29,610 | +9.0% | 0.02% | -4.2% |
Q2 2023 | $650,673 | +7.2% | 27,168 | -15.8% | 0.02% | 0.0% |
Q1 2023 | $607,076 | +147607.1% | 32,257 | +24.8% | 0.02% | +41.2% |
Q4 2022 | $411 | -99.9% | 25,846 | -1.8% | 0.02% | -15.0% |
Q3 2022 | $431,000 | +16.2% | 26,324 | +0.1% | 0.02% | +25.0% |
Q2 2022 | $371,000 | -26.5% | 26,309 | +26.2% | 0.02% | -11.1% |
Q1 2022 | $505,000 | +1.4% | 20,845 | -2.3% | 0.02% | +12.5% |
Q4 2021 | $498,000 | +27.4% | 21,332 | -9.3% | 0.02% | +14.3% |
Q3 2021 | $391,000 | -6.0% | 23,528 | +38.1% | 0.01% | -6.7% |
Q2 2021 | $416,000 | +61.2% | 17,043 | +109.5% | 0.02% | -34.8% |
Q4 2014 | $258,000 | -45.9% | 8,136 | -61.5% | 0.02% | -42.5% |
Q2 2014 | $477,000 | -49.7% | 21,131 | -44.3% | 0.04% | -58.8% |
Q4 2013 | $948,000 | -17.6% | 37,920 | -9.5% | 0.10% | -20.5% |
Q3 2013 | $1,151,000 | +14.0% | 41,895 | -24.7% | 0.12% | +1.7% |
Q2 2013 | $1,010,000 | – | 55,645 | – | 0.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Baker Brothers Advisors | 25,819,768 | $972,631,000 | 7.89% |
SECTORAL ASSET MANAGEMENT INC | 822,392 | $30,980,000 | 3.99% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 240,773 | $9,068,000 | 3.53% |
HARVEY CAPITAL MANAGEMENT INC | 230,700 | $8,690,000 | 3.51% |
Palo Alto Investors LP | 1,641,030 | $61,818,000 | 2.60% |
GARRISON BRADFORD & ASSOCIATES INC | 73,350 | $2,763,000 | 2.31% |
EMORY UNIVERSITY | 52,977 | $1,996,000 | 1.58% |
Sivik Global Healthcare LLC | 120,000 | $4,520,000 | 1.54% |
Stanley-Laman Group, Ltd. | 143,876 | $5,420,000 | 1.45% |
ACUTA CAPITAL PARTNERS, LLC | 170,000 | $6,404,000 | 1.15% |